Skip to main content

Anebulo Pharmaceuticals, Inc.

ANEB
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001815974

No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Holders of 5% or more of ANEB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Anebulo Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ANEB
HolderLatest formStakeChangeFirst filedLatest filingFiling
English Aron R.13D/A51.10%21.9M shares0.00 ppfrom 51.10%Dec 26, 20242 filingsFeb 27, 2025SEC
Nantahala Capital Management, LLC13G/A8.53%3.55M shares−0.10 ppfrom 8.63%Feb 14, 20252 filingsFeb 13, 2026SEC
Mangrove Partners13G6.15%2.53M sharesNewMar 17, 20251 filingMar 17, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Anebulo Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ANEB
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 13, 20265:00 PM ETNantahala Capital Management, LLCand 2 others13G/A8.53%3.55M shares−0.10 ppfrom 8.63%Dec 31, 2025SEC
Mar 17, 20254:51 PM ETMangrove Partnersand 1 other13G6.15%2.53M sharesNewDec 31, 2024SEC
Feb 27, 20257:41 AM ETEnglish Aron R.and 2 others13D/A51.10%21.9M shares0.00 ppfrom 51.10%Feb 24, 2025SEC
Feb 14, 20254:32 PM ETNantahala Capital Management, LLCand 2 others13G8.63%3.55M sharesNewDec 31, 2024SEC
Dec 26, 20249:42 PM ETEnglish Aron R.and 2 others13D/A51.10%21.9M shares–Dec 23, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Anebulo Pharmaceuticals, Inc. shares.

No Form 144 notices for Anebulo Pharmaceuticals, Inc. are on file.